Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We're fortunate and grateful in the hypertension world to have had more trials come to publication in the last few years, and there's been increased momentum and excitement around hypertension research that maybe wasn't there a decade or so ago. The evidence has been accumulating, and that accumulation has sped up in the recent years, so we're happy to have the opportunity to synthesize that evidence with this new guideline.”
“The 2024 ESC-HTGL have introduced a new BP category called 'Elevated' BP, which is defined as an office systolic BP of 120–139 mmHg or a diastolic BP of 70–89 mmHg. Many people within the 'Elevated' BP range will have an estimated 10-year global risk for CV events ≥10%, which, according to the 2024 ESC-HTGL, is sufficient to merit BP-lowering drug treatment for people with BP in the 130–139/80–89 mmHg range.”
“These more simple categories will help us in our daily practice.”
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: